Summary
Karyopharm delivered one of the most important myelofibrosis datasets of 2026. In the Phase 3 SENTRY study, selinexor plus ruxolitinib nearly doubled spleen response rates versus ruxolitinib alone (49.8% vs 28.0%) and generated an early overall survival signal (HR 0.43). However, the trial missed its co-primary symptom endpoint and showed higher rates of grade 3+ adverse events, creating a complex regulatory and commercial picture.
What Happened
SENTRY met its key efficacy endpoint with statistically significant improvement in SVR35 at week 24. The combination also demonstrated reductions in mutant allele burden and an early survival advantage. However, the Absolute Total Symptom Score endpoint failed to achieve statistical significance. Grade 3 or higher treatment-emergent adverse events occurred in 70% of patients receiving selinexor plus ruxolitinib versus 50% in the control arm.
Deep Analysis
The headline number is not the missed symptom endpoint—it is the magnitude of the SVR35 and survival signals. A nearly 22-point absolute improvement in spleen response is clinically meaningful in frontline myelofibrosis and compares favorably with historical combination studies.
More importantly, the HR of 0.43 is the most provocative finding in the dataset. No currently approved frontline MF therapy has demonstrated this magnitude of survival benefit against ruxolitinib in a randomized study. While immature and requiring longer follow-up, the signal raises the possibility that selinexor may be affecting underlying disease biology rather than simply controlling symptoms.
The allele burden reductions reinforce this hypothesis. If confirmed, this would move the conversation from symptom management toward disease modification, one of the major unmet needs in MF.
The regulatory challenge is that symptom improvement remains important in MF approvals. FDA will need to determine whether strong spleen responses, potential survival benefit, and molecular signals outweigh the missed symptom endpoint and increased toxicity burden.
Competitive Displacement
The data directly pressure ruxolitinib monotherapy as the frontline standard. The results also increase competitive pressure on GSK’s momelotinib and other next-generation JAK inhibitor strategies.
For Lilly’s recently acquired Ajax Type II JAK2 inhibitor program, SENTRY validates the concept that future MF treatment may increasingly rely on combination approaches rather than incremental improvements in JAK inhibition alone.
Company / Product Background
Selinexor is an oral inhibitor of Exportin-1 (XPO1), a nuclear export protein responsible for transporting tumor suppressor proteins out of the nucleus. By blocking XPO1, selinexor restores nuclear retention of key regulatory proteins and may enhance anti-tumor activity. Ruxolitinib remains the current JAK1/JAK2 inhibitor backbone for frontline myelofibrosis treatment.
Signal Extraction
- Near doubling of SVR35 response rate
- Unexpectedly strong early survival signal
- Evidence supporting disease-modification hypothesis
- Combination therapy narrative strengthened in MF
- Regulatory debate shifts toward benefit-risk assessment
Insilens Take
The market will focus on the missed symptom endpoint. Scientists and hematologists will focus on the survival signal and allele burden reductions.
If future follow-up confirms durability of the HR 0.43 benefit, SENTRY could become the first study to shift the MF field toward combination-based disease modification. The dataset is not clean enough to be paradigm changing today, but it is strong enough to make selinexor a serious contender for frontline MF adoption and regulatory review.
